Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H44N4O4S |
| Molecular Weight | 484.696 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCOC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)NC[C@H]2CC[C@H](N)CC2)C(C)(C)SC(C)C
InChI
InChIKey=MNMZVSQUWOILCZ-MUGJNUQGSA-N
InChI=1S/C24H44N4O4S/c1-6-14-32-23(31)27-20(24(4,5)33-16(2)3)22(30)28-13-7-8-19(28)21(29)26-15-17-9-11-18(25)12-10-17/h16-20H,6-15,25H2,1-5H3,(H,26,29)(H,27,31)/t17-,18-,19-,20-/m0/s1
| Molecular Formula | C24H44N4O4S |
| Molecular Weight | 484.696 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Mitsubishi Tanabe Pharma was developing Sofigatran, a thrombin inhibitor, for the treatment of deep vein thrombosis. Sofigatran, is a direct oral thrombin inhibitor with a competitive binding mechanism. It has been assessed in a phase II trial for the treatment of deep vein thrombosis The compound was in phase II clinical trial for the treatment of DVT. Results of this trial have not been published and the clinical development of sofigatran has been discontinued by Mitsubishi Tanabe Pharma in 2007.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:20:53 GMT 2025
by
admin
on
Mon Mar 31 19:20:53 GMT 2025
|
| Record UNII |
5X6P105U1Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C263
Created by
admin on Mon Mar 31 19:20:53 GMT 2025 , Edited by admin on Mon Mar 31 19:20:53 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C152382
Created by
admin on Mon Mar 31 19:20:53 GMT 2025 , Edited by admin on Mon Mar 31 19:20:53 GMT 2025
|
PRIMARY | |||
|
300000037023
Created by
admin on Mon Mar 31 19:20:53 GMT 2025 , Edited by admin on Mon Mar 31 19:20:53 GMT 2025
|
PRIMARY | |||
|
8751
Created by
admin on Mon Mar 31 19:20:53 GMT 2025 , Edited by admin on Mon Mar 31 19:20:53 GMT 2025
|
PRIMARY | |||
|
5X6P105U1Y
Created by
admin on Mon Mar 31 19:20:53 GMT 2025 , Edited by admin on Mon Mar 31 19:20:53 GMT 2025
|
PRIMARY | |||
|
187602-11-5
Created by
admin on Mon Mar 31 19:20:53 GMT 2025 , Edited by admin on Mon Mar 31 19:20:53 GMT 2025
|
PRIMARY | |||
|
DTXSID50940225
Created by
admin on Mon Mar 31 19:20:53 GMT 2025 , Edited by admin on Mon Mar 31 19:20:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
